Opendata, web and dolomites

BriScrew

BioResorbable Ostheosynthesis Implant

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BriScrew project word cloud

Explore the words cloud of the BriScrew project. It provides you a very rough idea of what is the project "BriScrew" about.

performed    sell    ca    removal    pain    market    introduce    alloyed    purified    payback    global    implant    13    disease    revolutionary    natural    zn    q3    implants    zirconium    screws    almost    temperature    minimize    prevent    conventional    unpredictable    pay    orthopaedic    hire    infections    employees    earth    2m    investment    aluminium    bioresorbable    merely    operation    generate    profit    95    surgery       engineering    off    medicine    sales    commercializing    earn    feeling    metal    materials    total    risks    surgical    injuries    2020    titanium    foresee    steel    risk    silver    biodegradable    roi    reduces    qualified    launch    organism    magnesium    81    rare    patient    stiff    bone    screw    treatment    adverse    gold    healing    quality    900    shielding    fractures    7m    alloy    frequently    time    secondary    consists    too    stress    commercialization    composition    standard    individuals    team    extremely    mg    assurance    bri    healthcare    stimulates    remove    osteosynthesis    hospital   

Project "BriScrew" data sheet

The following table provides information about the project.

Coordinator
BRI.TECH GMBH 

Organization address
address: ROSSMANNGASSE 21/4
city: GRAZ
postcode: 8010
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Austria [AT]
 Project website http://britech.eu/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-03-01   to  2017-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BRI.TECH GMBH AT (GRAZ) coordinator 50˙000.00

Map

 Project objective

In the EU, 20 % of all hospital treated injuries are bone fractures. If surgical treatment of bone fractures is necessary, it is currently performed with standard metal implants. Conventional gold-standard titanium or steel implants are too stiff, have adverse effects on the patient (feeling of pain during temperature changes) and lead to stress-shielding. Their usage is associated to the risk of infections and bone loss. Often a secondary surgery for removal is needed which is associated with almost 50 % higher healthcare costs. When Mg-based implants are used they are frequently alloyed with rare earth elements, aluminium, silver or zirconium. However, zirconium reduces the healing properties, aluminium and rare earth elements may remain in the organism and can lead to unpredictable effects, while the application of silver might result in a silver-disease.

Within the BRI.SCREW project we will introduce to the market revolutionary osteosynthesis implants that do not need surgical removal. We will use our own bioresorbable magnesium alloy which consists merely out of extremely high purified natural materials including Mg, Ca and Zn. BRI.SCREW is 100 % biodegradable, stimulates the healing process of the bone and has no side effects due to the implant's composition. Our orthopaedic implants will prevent the need of a second operation to remove the implant and will therefore minimize patient costs and surgical risks.

Our team consists of highly qualified individuals with experience in medicine, engineering and quality assurance. The investment in BRI.SCREW will pay off. We have estimated that after 5 years from launch, we will sell in total 81.900 BRI.SCREWs (sales €13.2M), hire 10 technical employees, and manage 5% of the global market. We will earn €8.7M profit and generate a ROI of 3.95 by commercializing this technology. We foresee the payback time in 2 years after commercialization (in Q3 of 2020).

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BRISCREW" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BRISCREW" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

ESCALON (2019)

European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development

Read More  

CLOSER (2019)

Childhood Leukemia: Overcoming distance between South America and Europe Regions

Read More  

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More